Pyxis Oncology (PYXS) Net Income towards Common Stockholders Growth (1y) (2021 - 2025)
Pyxis Oncology (PYXS) Net Income towards Common Stockholders Growth (1y) (2021 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-129.68% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-290.15% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Pyxis Oncology |
125.84 Mn |
108.95 Mn |
8.65 Mn |
49.06% |
| Date | Value |
|---|
| Dec 31, 2025 |
49.06% |
| Sep 30, 2025 |
-3.77% |
| Jun 30, 2025 |
-4.45% |
| Mar 31, 2025 |
-305.63% |
| Dec 31, 2024 |
-119.94% |
| Sep 30, 2024 |
10.34% |
| Jun 30, 2024 |
-5.08% |
| Mar 31, 2024 |
73.13% |
| Dec 31, 2023 |
55.20% |
| Sep 30, 2023 |
14.55% |
| Jun 30, 2023 |
35.59% |
| Mar 31, 2023 |
36.62% |
| Dec 31, 2022 |
-119.87% |
| Sep 30, 2022 |
-138.26% |
| Jun 30, 2022 |
-330.70% |
| Mar 31, 2022 |
12.16% |
| Dec 31, 2021 |
-258.57% |
| Sep 30, 2021 |
-263.99% |
